|Bid||88.44 x 800|
|Ask||90.00 x 900|
|Day's Range||85.87 - 89.04|
|52 Week Range||71.59 - 92.57|
|Beta (5Y Monthly)||0.49|
|PE Ratio (TTM)||2,455.00|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||115.89|
Subscribe to Yahoo Finance Plus to view Fair Value for BMRNLearn more
NEW YORK, NY / ACCESSWIRE / December 8, 2021 / The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of BioMarin Pharmaceutical Inc. ("BioMarin") (NASDAQ:BMRN) between January 13, 2020 and September 3, 2021.
LOS ANGELES, CA / ACCESSWIRE / December 8, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstBioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ:BMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.
NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities bet